Needham Reiterates Buy on Biogen, Maintains $320 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $320.
July 25, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Biogen and maintained a price target of $320.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $320 price target indicates a positive outlook for Biogen. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100